Home > Medical Reference > Complementary Medicine

Fluoxetine


Special Alerts

Antidepressant Use in Pediatric Patients - October 15, 2004

In March 2004, the Food and Drug Administration (FDA) issued a Public Health Advisory concerning the use of antidepressant medications in which they called attention to reports of both suicidal ideation and suicide attempts in children taking antidepressant drugs for the treatment of major depressive disorder (MDD). In September 2004, a review of the existing data was completed by two FDA Advisory Committees. The FDA has now instructed the manufacturers of ALL antidepressants to revise the labeling for their products to include a boxed warning and expanded warning statements that alert healthcare providers to an increased risk of suicidality (suicidal thinking and behavior) in children and adolescents being treated with these agents, and to include additional information about the results of pediatric studies. The FDA also informed manufacturers that a Patient Medication Guide (MedGuide), which will be given to patients receiving the drugs advising them of the risk and precautions, is appropriate for these drug products.

The risk of suicidality for these drugs was identified in a combined analysis of short-term (up to 4 months) placebo-controlled trials of nine antidepressant drugs, including the selective serotonin reuptake inhibitors (SSRIs) and others, in children and adolescents with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders. A total of 24 trials involving over 4400 patients were included. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants. The average risk of such events on drug was 4%, compared to a rate of 2% in groups receiving placebo. No suicides occurred in these trials. Based on this data, the FDA has determined that the following points are appropriate for inclusion in the boxed warning:

Antidepressants increase the risk of suicidal thinking and behavior (suicidality) in children and adolescents with MDD and other psychiatric disorders.

Anyone considering the use of an antidepressant in a child or adolescent for any clinical use must balance the risk of increased suicidality with the clinical need.

Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior.

Families and caregivers should be advised to closely observe the patient and to communicate with the prescriber.

A statement regarding whether the particular drug is approved for any pediatric indication(s) and, if so, which one(s).

Among the antidepressants, only fluoxetine is approved for use in treating MDD in pediatric patients. Clomipramine, fluoxetine, fluvoxamine, and sertraline are approved for OCD in pediatric patients. None of the drugs is FDA approved for other psychiatric indications in children.

Pediatric patients being treated with antidepressants for any indication should be closely observed for clinical worsening, as well as agitation, irritability, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes (either increases or decreases). This monitoring should include daily observation by families and caregivers and frequent contact with the physician. It is also recommended that prescriptions for antidepressants be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.

In addition to the boxed warning and other information in professional labeling on antidepressants, MedGuides are being prepared for all of the antidepressants to provide information about the risk of suicidality in children and adolescents for patients and their families and caregivers. MedGuides are intended to be distributed by the pharmacist with each prescription or refill of a medication.

The FDA plans to work closely with the manufacturers of all approved antidepressant products to optimize the safe use of these drugs and implement the proposed labeling changes and other safety communications in a timely manner.

Additional information can be found on the FDA website at: http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#ssri, last accessed October 21, 2004.


Pronunciation

 (floo OKS e teen)


U.S. Brand Names

 Prozac®; Prozac® Weekly™; Sarafem™


Synonyms

 Fluoxetine Hydrochloride


Generic Available

 Yes; Excludes delayed release capsule


Canadian Brand Names

 Alti-Fluoxetine; Apo-Fluoxetine®; CO Fluoxetine; FXT; Gen-Fluoxetine; Novo-Fluoxetine; Nu-Fluoxetine; PMS-Fluoxetine; Prozac®; Rhoxal-fluoxetine


Use

 Treatment of major depressive disorder; treatment of binge-eating and vomiting in patients with moderate-to-severe bulimia nervosa; obsessive-compulsive disorder (OCD); premenstrual dysphoric disorder (PMDD); panic disorder with or without agoraphobia


Use - Unlabeled/Investigational

 Selective mutism


Pregnancy Risk Factor

 C


Pregnancy Implications

 Fluoxetine crosses the placenta. Nonteratogenic effects including respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor have been reported in the neonate immediately following delivery after exposure to other SSRIs late in the third trimester. Adverse effects may be due to toxic effects of SSRI or drug discontinuation. In some cases, may present clinically as serotonin syndrome. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit to the mother outweighs the possible risk to the fetus. If treatment during pregnancy is required, consider tapering SSRI therapy during the third trimester.


Lactation

 Enters breast milk/not recommended (AAP rates "of concern")


Contraindications

 Hypersensitivity to fluoxetine or any component of the formulation; patients currently receiving MAO inhibitors, thioridazine, or mesoridazine

Note: MAO inhibitor therapy must be stopped for 14 days before fluoxetine is initiated. Treatment with MAO inhibitors, thioridazine, or mesoridazine should not be initiated until 5 weeks after the discontinuation of fluoxetine.


Warnings/Precautions

 Potential for severe reaction when used with MAO inhibitors; serotonin syndrome (hyperthermia, muscular rigidity, mental status changes/agitation, autonomic instability) may occur. Fluoxetine may elevate plasma levels of thioridazine and increase the risk of QTc interval prolongation. This may lead to serious ventricular arrhythmias such as torsade de pointes-type arrhythmias and sudden death. Fluoxetine use has been associated with occurrences of significant rash and allergic events, including vasculitis, lupus-like syndrome, laryngospasm, anaphylactoid reactions, and pulmonary inflammatory disease.

May precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. May cause insomnia, anxiety, nervousness or anorexia. Use with caution in patients where weight loss is undesirable. May impair cognitive or motor performance; caution operating hazardous machinery or driving. The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Monitor for worsening of depression or suicidality, especially during initiation of therapy or with dose increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.

Antidepressants increase the risk of suicidal thinking and behavior in children and adolescents with MDD and other depressive disorders; consider risk prior to prescribing. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior; the child's family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide should be dispensed with each prescription. Fluoxetine is FDA approved for the treatment of OCD in children 7 years of age and MDD in children 8 years of age.

Use caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage, alcoholism, or concurrent therapy with other drugs which lower the seizure threshold. Use with caution in patients with hepatic or renal dysfunction and in elderly patients. May cause hyponatremia/SIADH. May increase the risks associated with electroconvulsive treatment. Use with caution in patients at risk of bleeding or receiving concurrent anticoagulant therapy - may cause impairment in platelet function. May alter glycemic control in patients with diabetes. Due to the long half-life of fluoxetine and its metabolites, the effects and interactions noted may persist for prolonged periods following discontinuation. May cause or exacerbate sexual dysfunction. Discontinuation symptoms (eg, dysphoric mood, irritability, agitation, confusion, anxiety, insomnia, hypomania) may occur upon abrupt discontinuation. Taper dose when discontinuing therapy.


Adverse Reactions

 Percentages listed for adverse effects as reported in placebo-controlled trials and were generally similar in adults and children; actual frequency may be dependent upon diagnosis and in some cases the range presented may be lower than or equal to placebo for a particular disorder.

>10%:

Central nervous system: Insomnia (10% to 33%), headache (21%), anxiety (6% to 15%), nervousness (8% to 14%), somnolence (5% to 17%)

Endocrine & metabolic: Libido decreased (1% to 11%)

Gastrointestinal: Nausea (12% to 29%), diarrhea (8% to 18%), anorexia (4% to 11%), xerostomia (4% to 12%)

Neuromuscular & skeletal: Weakness (7% to 21%), tremor (3% to 13%)

Respiratory: Pharyngitis (3% to 11%), yawn (<1% to 11%)

1% to 10%:

Cardiovascular: Vasodilation (1% to 5%), fever (2%), chest pain, hemorrhage, hypertension, palpitation

Central nervous system: Dizziness (9%), dream abnormality (1% to 5%), thinking abnormality (2%), agitation, amnesia, chills, confusion, emotional lability, sleep disorder

Dermatologic: Rash (2% to 6%), pruritus (4%)

Endocrine & metabolic: Ejaculation abnormal (<1% to 7%), impotence (<1% to 7%)

Gastrointestinal: Dyspepsia (6% to 10%), constipation (5%), flatulence (3%), vomiting (3%), weight loss (2%), appetite increased, taste perversion, weight gain

Genitourinary: Urinary frequency

Ocular: Vision abnormal (2%)

Otic: Ear pain, tinnitus

Respiratory: Sinusitis (1% to 6%)

Miscellaneous: Flu-like syndrome (3% to 10%), diaphoresis (2% to 8%)

<1%, postmarketing and/or case reports: Acne, albuminuria, allergies, alopecia, amenorrhea, anaphylactoid reactions, anemia, angina, aphthous stomatitis, arrhythmia, arthritis, asthma, bone pain, bruising, bursitis, cataract, CHF, cholelithiasis, cholestatic jaundice, colitis, dehydration, dyskinesia, dysphagia, ecchymosis, edema, eosinophilic pneumonia, epistaxis, erythema nodosum, esophagitis, euphoria, exfoliative dermatitis, extrapyramidal symptoms (rare), gastritis, glossitis, gout, gynecomastia, hallucinations, hepatic failure/necrosis, hemorrhage, hiccup, hostility, hypercholesteremia, hyperprolactinemia, hyperventilation, hypoglycemia, hypokalemia, hypotension, hypothyroidism, immune-related hemolytic anemia, kidney failure, laryngospasm, leg cramps, liver function test abnormalities, lupus-like syndrome, malaise, migraine, misuse/abuse, MI, neuroleptic malignant syndrome (NMS), optic neuritis, pancreatitis, pancytopenia, photosensitivity reaction, postural hypotension, priapism, pulmonary embolism, pulmonary hypertension, QT prolongation, serotonin syndrome, Stevens-Johnson syndrome, suicidal ideation, syncope, tachycardia, tinnitus, thrombocytopenia, thrombocytopenic purpura, vasculitis, ventricular tachycardia (including torsade de pointes)


Overdosage/Toxicology

 Among 633 adult patients who overdosed on fluoxetine alone, 34 resulted in a fatal outcome. Symptoms of overdose include ataxia, sedation, coma, and ECG abnormalities (QT prolongation, torsade de pointes). Respiratory depression may occur, especially with coingestion of ethanol or other drugs. Seizures rarely occur. Treatment is supportive.


Drug Interactions

 Substrate of CYP1A2 (minor), 2B6 (minor), 2C8/9 (major), 2C19 (minor), 2D6 (major), 2E1 (minor), 3A4 (minor); Inhibits CYP1A2 (moderate), 2B6 (weak), 2C8/9 (weak), 2C19 (moderate), 2D6 (strong), 3A4 (weak)

Amphetamines: SSRIs may increase the sensitivity to amphetamines, and amphetamines may increase the risk of serotonin syndrome.

Benzodiazepines: Fluoxetine may inhibit the metabolism of alprazolam and diazepam resulting in elevated serum levels; monitor for increased sedation and psychomotor impairment.

Beta-blockers: Fluoxetine may inhibit the metabolism of metoprolol and propranolol resulting in cardiac toxicity; monitor for bradycardia, hypotension, and heart failure if combination is used; not established for all beta-blockers (unlikely with atenolol or nadolol due to renal elimination).

Buspirone: Fluoxetine inhibits the reuptake of serotonin; combined use with a serotonin agonist (buspirone) may cause serotonin syndrome.

Carbamazepine: Fluoxetine may inhibit the metabolism of carbamazepine resulting in increased carbamazepine levels and toxicity; monitor for altered carbamazepine response.

Carvedilol: Serum concentrations may be increased; monitor carefully for increased carvedilol effect (hypotension and bradycardia).

Clozapine: Fluoxetine may increase serum levels of clozapine; levels may increase by 76%; monitor for increased effect/toxicity.

Cyclosporine: Fluoxetine may increase serum levels of cyclosporine (and possibly tacrolimus); monitor.

CYP1A2 substrates: Fluoxetine may increase the levels/effects of CYP1A2 substrates. Example substrates include aminophylline, fluvoxamine, mexiletine, mirtazapine, ropinirole, theophylline, and trifluoperazine.

CYP2C8/9 inducers: May decrease the levels/effects of fluoxetine. Example inducers include carbamazepine, phenobarbital, phenytoin, rifampin, rifapentine, and secobarbital.

CYP2C8/9 inhibitors: May increase the levels/effects of fluoxetine. Example inhibitors include delavirdine, fluconazole, gemfibrozil, ketoconazole, nicardipine, NSAIDs, pioglitazone, and sulfonamides.

CYP2C19 substrates: Fluoxetine may increase the levels/effects of CYP2C19 substrates. Example substrates include citalopram, diazepam, methsuximide, phenytoin, propranolol, and sertraline.

CYP2D6 inhibitors: May increase the levels/effects of fluoxetine. Example inhibitors include chlorpromazine, delavirdine, miconazole, paroxetine, pergolide, quinidine, quinine, ritonavir, and ropinirole.

CYP2D6 substrates: Fluoxetine may increase the levels/effects of CYP2D6 substrates. Example substrates include amphetamines, selected beta-blockers, dextromethorphan, lidocaine, mirtazapine, nefazodone, paroxetine, risperidone, ritonavir, thioridazine, tricyclic antidepressants, and venlafaxine.

CYP2D6 prodrug substrates: Fluoxetine may decrease the levels/effects of CYP2D6 prodrug substrates. Example prodrug substrates include codeine, hydrocodone, oxycodone, and tramadol.

Cyproheptadine: May inhibit the effects of serotonin reuptake inhibitors (fluoxetine); monitor for altered antidepressant response; cyproheptadine acts as a serotonin agonist.

Dextromethorphan: Fluoxetine inhibits the metabolism of dextromethorphan; visual hallucinations occurred in a patient receiving this combination; monitor for serotonin syndrome.

Digoxin: Fluoxetine may increase serum levels of digoxin; monitor.

Haloperidol: Fluoxetine may inhibit the metabolism of haloperidol and cause extrapyramidal symptoms (EPS); monitor patients for EPS if combination is utilized.

HMG-CoA reductase inhibitors: Fluoxetine may inhibit the metabolism of lovastatin and simvastatin resulting in myositis and rhabdomyolysis; these combinations are best avoided.

Lithium: Reports of both increased and decreased lithium levels when used concomitantly with fluoxetine. Patients receiving fluoxetine and lithium have developed neurotoxicity. If combination is used; monitor lithium levels and for neurotoxicity.

Loop diuretics: Fluoxetine may cause hyponatremia; additive hyponatremic effects may be seen with combined use of a loop diuretic (bumetanide, furosemide, torsemide); monitor for hyponatremia.

MAO inhibitors: Combined use of fluoxetine with nonselective MAOIs (ie, isocarboxazid, phenelzine) is contraindicated; fatal reactions have been reported; wait 5 weeks after stopping fluoxetine before starting an MAO inhibitor and 2 weeks after stopping an MAO inhibitor before starting fluoxetine.

Meperidine: Combined use with fluoxetine theoretically may increase the risk of serotonin syndrome.

Mesoridazine: Fluoxetine may inhibit the metabolism of mesoridazine, resulting in increased plasma levels and increasing the risk of QTc interval prolongation. This may lead to serious ventricular arrhythmias, such as torsade de pointes-type arrhythmias and sudden death. Do not use concurrently. Wait at least 5 weeks after discontinuing fluoxetine prior to starting mesoridazine.

Nefazodone: May increase the risk of serotonin syndrome with SSRIs; monitor.

NSAIDs: Concomitant use of fluoxetine and NSAIDs, aspirin, or other drugs affecting coagulation has been associated with an increased risk of bleeding; monitor.

Phenytoin: Fluoxetine inhibits the metabolism of phenytoin and may result in phenytoin toxicity; monitor for phenytoin toxicity (ataxia, confusion, dizziness, nystagmus, involuntary muscle movement).

Propafenone: Serum concentrations and/or toxicity may be increased by fluoxetine; avoid concurrent administration.

Ritonavir: Combined use of fluoxetine with ritonavir may cause serotonin syndrome in HIV-positive patients; monitor.

Selegiline: Fluoxetine has been reported to cause mania or hypertension when combined with selegiline; this combination is best avoided. Concurrent use with SSRIs has also been reported to cause serotonin syndrome. As a MAO type B inhibitor, the risk of serotonin syndrome may be less than with nonselective MAO inhibitors.

Sibutramine: May increase the risk of serotonin syndrome with SSRIs; avoid coadministration.

SSRIs: Fluoxetine inhibits the reuptake of serotonin; combined use with other drugs which inhibit the reuptake may cause serotonin syndrome.

Sumatriptan (and other serotonin agonists): Concurrent use may result in toxicity; weakness, hyper-reflexia, and incoordination have been observed with sumatriptan and SSRIs. In addition, concurrent use may theoretically increase the risk of serotonin syndrome; includes sumatriptan, naratriptan, rizatriptan, and zolmitriptan.

Sympathomimetics: May increase the risk of serotonin syndrome with SSRIs.

Thioridazine: Fluoxetine may inhibit the metabolism of thioridazine, resulting in increased plasma levels and increasing the risk of QTc interval prolongation. This may lead to serious ventricular arrhythmias, such as torsade de pointes-type arrhythmias and sudden death. Do not use together. Wait at least 5 weeks after discontinuing fluoxetine prior to starting thioridazine.

Tramadol: Fluoxetine combined with tramadol (serotonergic effects) may cause serotonin syndrome; monitor.

Trazodone: Fluoxetine may inhibit the metabolism of trazodone resulting in increased toxicity; monitor.

Tricyclic antidepressants: Fluoxetine inhibits the metabolism of tricyclic antidepressants (amitriptyline, desipramine, imipramine, nortriptyline) resulting is elevated serum levels; if combination is warranted, a low dose of TCA (10-25 mg/day) should be utilized.

Tryptophan: Fluoxetine inhibits the reuptake of serotonin; combination with tryptophan, a serotonin precursor, may cause agitation and restlessness; this combination is best avoided.

Valproic acid: Fluoxetine may increase serum levels of valproic acid; monitor.

Venlafaxine: Fluoxetine may increase the risk of serotonin syndrome.

Warfarin: Fluoxetine may alter the hypoprothrombinemic response to warfarin; monitor.


Ethanol/Nutrition/Herb Interactions

Ethanol: Avoid ethanol (may increase CNS depression). Depressed patients should avoid/limit intake.

Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).


Stability

 All dosage forms should be stored at controlled room temperature of 15°C to 30°C (50°F to 86°F); oral liquid should be dispensed in a light-resistant container


Mechanism of Action

 Inhibits CNS neuron serotonin reuptake; minimal or no effect on reuptake of norepinephrine or dopamine; does not significantly bind to alpha-adrenergic, histamine, or cholinergic receptors


Pharmacodynamics/Kinetics

Absorption: Well absorbed; delayed 1-2 hours with weekly formulation

Protein binding: 95%

Metabolism: Hepatic to norfluoxetine (active; equal to fluoxetine)

Half-life elimination: Adults:

Parent drug: 1-3 days (acute), 4-6 days (chronic), 7.6 days (cirrhosis)

Metabolite (norfluoxetine): 9.3 days (range: 4-16 days), 12 days (cirrhosis)

Due to long half-life, resolution of adverse reactions after discontinuation may be slow

Time to peak: 6-8 hours

Excretion: Urine (10% as norfluoxetine, 2.5% to 5% as fluoxetine)

Note: Weekly formulation results in greater fluctuations between peak and trough concentrations of fluoxetine and norfluoxetine compared to once-daily dosing (24% daily/164% weekly; 17% daily/43% weekly, respectively). Trough concentrations are 76% lower for fluoxetine and 47% lower for norfluoxetine than the concentrations maintained by 20 mg once-daily dosing. Steady-state fluoxetine concentrations are ~50% lower following the once-weekly regimen compared to 20 mg once daily. Average steady-state concentrations of once-daily dosing were highest in children ages 6 to <13 (fluoxetine 171 ng/mL; norfluoxetine 195 ng/mL), followed by adolescents ages 13 to <18 (fluoxetine 86 ng/mL; norfluoxetine 113 ng/mL); concentrations were considered to be within the ranges reported in adults (fluoxetine 91-302 ng/mL; norfluoxetine 72-258 ng/mL).


Dosage

 Oral:

Children:

Depression: 8-18 years: 10-20 mg/day; lower-weight children can be started at 10 mg/day, may increase to 20 mg/day after 1 week if needed

OCD: 7-18 years: Initial: 10 mg/day; in adolescents and higher-weight children, dose may be increased to 20 mg/day after 2 weeks. Range: 10-60 mg/day

Selective mutism (unlabeled use):

<5 years: No dosing information available

5-18 years: Initial: 5-10 mg/day; titrate upwards as needed (usual maximum dose: 60 mg/day)

Adults: 20 mg/day in the morning; may increase after several weeks by 20 mg/day increments; maximum: 80 mg/day; doses >20 mg may be given once daily or divided twice daily. Note: Lower doses of 5-10 mg/day have been used for initial treatment.

Usual dosage range:

Bulimia nervosa: 60-80 mg/day

Depression: 20-40 mg/day; patients maintained on Prozac® 20 mg/day may be changed to Prozac® Weekly™ 90 mg/week, starting dose 7 days after the last 20 mg/day dose

OCD: 40-80 mg/day

Panic disorder: Initial: 10 mg/day; after 1 week, increase to 20 mg/day; may increase after several weeks; doses >60 mg/day have not been evaluated

PMDD (Sarafem™): 20 mg/day continuously, or 20 mg/day starting 14 days prior to menstruation and through first full day of menses (repeat with each cycle)

Elderly: Depression: Some patients may require an initial dose of 10 mg/day with dosage increases of 10 and 20 mg every several weeks as tolerated; should not be taken at night unless patient experiences sedation

Dosing adjustment in renal impairment:

Single dose studies: Pharmacokinetics of fluoxetine and norfluoxetine were similar among subjects with all levels of impaired renal function, including anephric patients on chronic hemodialysis

Chronic administration: Additional accumulation of fluoxetine or norfluoxetine may occur in patients with severely impaired renal function

Hemodialysis: Not removed by hemodialysis; use of lower dose or less frequent dosing is not usually necessary.

Dosing adjustment in hepatic impairment: Elimination half-life of fluoxetine is prolonged in patients with hepatic impairment; a lower or less frequent dose of fluoxetine should be used in these patients

Cirrhosis patients: Administer a lower dose or less frequent dosing interval

Compensated cirrhosis without ascites: Administer 50% of normal dose


Monitoring Parameters

 Mental status for depression, suicidal ideation, anxiety, social functioning, mania, panic attacks; akathisia, sleep


Reference Range

 Therapeutic levels have not been well established

Therapeutic: Fluoxetine: 100-800 ng/mL (SI: 289-2314 nmol/L); Norfluoxetine: 100-600 ng/mL (SI: 289-1735 nmol/L)

Toxic: Fluoxetine plus norfluoxetine: >2000 ng/mL


Dietary Considerations

 May be taken with or without food.


Patient Education

 Take exactly as directed; do not increase dose or frequency. It may take 2-3 weeks to achieve desired results. Take once-a-day dose in the morning to reduce incidence of insomnia. Avoid alcohol, caffeine, and other prescription or OTC medications not approved by prescriber. Maintain adequate hydration (2-3 L/day of fluids) unless instructed to restrict fluid intake. You may experience drowsiness, lightheadedness, impaired coordination, dizziness, or blurred vision (use caution when driving or engaging in tasks requiring alertness until response to drug is known); constipation (increased exercise, fluids, fruit, or fiber may help); anorexia (maintain regular dietary intake to avoid excessive weight loss); or postural hypotension (use caution when climbing stairs or changing position from lying or sitting to standing). If you have diabetes, monitor serum glucose closely (may cause hypoglycemia). Report persistent CNS effects (nervousness, restlessness, insomnia, anxiety, excitation, headache, sedation); rash or skin irritation; muscle cramping, tremors, or change in gait; respiratory depression or respiratory difficulty; or worsening of condition. Pregnancy/breast-feeding precautions: Inform prescriber if you are pregnant. Breast-feeding is not recommended.


Nursing Implications

 Offer patient sugarless hard candy for dry mouth


Additional Information

 ECG may reveal S-T segment depression; not shown to be teratogenic in rodents; 15-60 mg/day, buspirone and cyproheptadine, may be useful in treatment of sexual dysfunction during treatment with a selective serotonin reuptake inhibitor.

Weekly capsules are a delayed release formulation containing enteric-coated pellets of fluoxetine hydrochloride, equivalent to 90 mg fluoxetine. Therapeutic equivalence of weekly formulation with daily formulation for delaying time to relapse has not been established.


Anesthesia and Critical Care Concerns/Other Considerations

 SSRIs are relatively safe compared to other antidepressants in patients with cardiovascular disease.

Buspirone and cyproheptadine, may be useful in treatment of sexual dysfunction during treatment with a selective serotonin reuptake inhibitor.

Weekly capsules are a delayed release formulation containing enteric-coated pellets of fluoxetine hydrochloride, equivalent to 90 mg fluoxetine. Therapeutic equivalence of weekly formulation with daily formulation for delaying time to relapse has not been established.


Cardiovascular Considerations

 SSRIs alone are relatively safe compared to other antidepressants in patients with cardiovascular disease. SSRIs may increase the risk of QT prolongation/torsade de pointes associated with other drugs administered concurrently. Fluoxetine is being evaluated in experimental studies for vasovagal syncope. Fluoxetine may decrease the metabolism of thioridazine possibly predisposing to thioridazine-induced QT interval prolongation. Thioridazine should not be used in combination with fluoxetine and should be dosed at least 5 weeks after fluoxetine is discontinued.


Dental Health: Effects on Dental Treatment

 Key adverse event(s) related to dental treatment: Xerostomia (normal salivary flow resumes upon discontinuation) and taste perversion. Problems with SSRI-induced bruxism have been reported and may preclude their use; clinicians attempting to evaluate any patient with bruxism or involuntary muscle movement, who is simultaneously being treated with an SSRI drug, should be aware of this potential association.


Dental Health: Vasoconstrictor/Local Anesthetic Precautions

 Although caution should be used in patients taking tricyclic antidepressants, no interactions have been reported with vasoconstrictors and fluoxetine, a nontricyclic antidepressant which acts to increase serotonin


Mental Health: Child/Adolescent Considerations

 A study in children 8-15 years of age with obsessive compulsive disorder (n=14) used a fixed dose of 20 mg/day (Riddle, 1992). A study of children 10-18 years of age with obsessive compulsive symptoms and Tourette's syndrome (n=5) used 20-40 mg/day (Kurlan, 1993). Six children 6-12 years of age with selective mutism were treated with initial doses of 0.2 mg/kg/day for 1 week, then 0.4 mg/kg/day for 1 week, then 0.6 mg/kg/day for 10 weeks (Black, 1994). Twenty-one children (mean age: 8.2 years) with selective mutism received a mean end dose of 28.1 mg (10-60 mg) in a 9 week open trial (Dummit, 1996). Ninety-six outpatients 7-17 years of age with nonpsychotic major depression received 20 mg/day (Emslie, 1997); further studies are needed.

Black B and Uhde TW, "Treatment of Elective Mutism With Fluoxetine: A Double Blind, Placebo-Controlled Study," J Am Acad Child Adolesc Psychiatry , 1994, 33(7):1000-6.

Dummit ES 3rd, Klein RG, Tancer NK, et al, "Fluoxetine Treatment of Children With Selective Mutism: An Open Trial," J Am Acad Child Adolesc Psychiatry , 1996, 35(5):615-21.

Emslie GJ, Rush AJ, Weinberg WA, et al, "A Double-Blind, Randomized, Placebo-Controlled Trial of Fluoxetine in Children and Adolescents With Depression," Arch Gen Psychiatry , 1997, 54(11):1031-7.

Kurlan R, Como PG, Deeley C, et al, "A Pilot Controlled Study of Fluoxetine for Obsessive-Compulsive Symptoms in Children With Tourette's Syndrome," Clin Neuropharmacol , 1993, 16(2):167-72.

Riddle MA, Scahill L, King RA, et al, "Double-Blind, Crossover Trial of Fluoxetine and Placebo in Children and Adolescents With Obsessive-Compulsive Disorder," J Am Acad Child Adolesc Psychiatry , 1992, 31(6):1062-9.


Dosage Forms

Capsule, as hydrochloride: 10 mg, 20 mg, 40 mg

Prozac®: 10 mg, 20 mg, 40 mg

Sarafem™: 10 mg, 20 mg

Capsule, delayed release, as hydrochloride (Prozac® Weekly™): 90 mg

Solution, oral, as hydrochloride (Prozac®): 20 mg/5 mL (120 mL) [contains alcohol 0.23% and benzoic acid; mint flavor]

Tablet, as hydrochloride: 10 mg, 20 mg

Prozac® [scored]: 10 mg


Extemporaneously Prepared

 A 20 mg capsule may be mixed with 4 oz of water, apple juice, or Gatorade® to provide a solution that is stable for 14 days under refrigeration


References

"American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk," Pediatrics , 2001, 108(3):776-89.

Amitai Y, Kennedy E, De Sandre P, et al, "Red Cell and Plasma Concentrations of Fluoxetine and Norfluoxetine," Vet Hum Toxicol , 1993, 35(2):134-6.

Beasley CM, Bosomworth JC, and Wernicke JF, "Fluoxetine: Relationships Among Dose, Response, Adverse Events, and Plasma Concentrations in the Treatment of Depression," Psychopharmacol Bull , 1990, 26(1):18-24.

Black B and Uhde TW, "Treatment of Elective Mutism With Fluoxetine: A Double Blind, Placebo-Controlled Study," J Am Acad Child Adolesc Psychiatry , 1994, 33(7):1000-6.

Borys DJ, Setzer SC, Ling LJ, et al, "Acute Fluoxetine Overdose: A Report of 234 Cases," Am J Emerg Med , 1992, 10(2):115-20.

Borys DJ, Setzer SC, Ling LJ, et al, "The Effects of Fluoxetine in the Overdose Patient," J Toxicol Clin Toxicol , 1990, 28(3):331-40.

Braitberg G and Curry SC, "Seizure After Isolated Fluoxetine Overdose," Ann Emerg Med , 1995, 26(2):234-7.

Como PG and Kurlan R, "An Open-Label Trial of Fluoxetine for Obsessive-Compulsive Disorder in Gilles de la Tourette's Syndrome," Neurology , 1991, 41(6):872-4.

Dummit ES 3rd, Klein RG, Tancer NK, et al, "Fluoxetine Treatment of Children With Selective Mutism: An Open Trial," J Am Acad Child Adolesc Psychiatry , 1996, 35(5):615-21.

Emslie GJ, Rush AJ, Weinberg WA, et al, "A Double-Blind, Randomized, Placebo-Controlled Trial of Fluoxetine in Children and Adolescents With Depression," Arch Gen Psychiatry , 1997, 54(11):1031-7.

Feighner JP and Cohn JB, "Double-blind Comparative Trials of Fluoxetine and Doxepin in Geriatric Patients With Major Depressive Disorder," J Clin Psychiatry , 1985, 46(3 Pt 2):20-5.

Garcia-Monco JC, Padierna A, and Gomez Beldarrain M, "Selegiline, Fluoxetine, and Depression in Parkinson's Disease," Mov Disord , 1995, 10(3):352.

Gardner SF, Rutherford WF, Munger MA, et al, "Drug-Induced Supraventricular Tachycardia: A Case Report of Fluoxetine," Ann Emerg Med , 1991, 20(2):194-7.

Gonzalez-Rothi RJ, Zander DS, and Ros PR, "Fluoxetine Hydrochloride (Prozac®)-Induced Pulmonary Disease," Chest , 1995, 107(6):1763-5.

Grassi B, Gambini O, and Scarone S, "Severe Bradycardia Following Fluoxetine Administration: A Case Report in a Young HIV-1 Infected Woman," Human Psychopharmacology: Clinical and Experimental , 1995, 10:153-5.

Grounds D, Stocky A, Evans P, et al, "Antidepressants and Side Effects," Aust N Z J Psychiatry , 1995, 29(1):156-7.

Hofman M and Liu JK, "Conduction Abnormality and Ventricular Tachyarrhythmia Associated With Fluoxetine Overdose," Vet Hum Toxicol , 1994, 36:371.

Horton RC and Bonser RS, "Interaction Between Cyclosporin and Fluoxetine," BMJ , 1995, 311(7002):422.

Jackson C, Carson W, Markowitz J, et al, "SIADH Associated With Fluoxetine and Sertraline Therapy," Am J Psychiatry , 1995, 152(5):809-10.

Jennison TA, Brown P, Crossett J, et al, "A High-Performance Liquid Chromatographic Method for Quantitating Bupropion in Human Plasma or Serum," J Anal Toxicol , 1995, 19(2):69-72.

Kingsbury SJ and Puckett KM, "Effects of Fluoxetine on Serum Clozapine Levels," Am J Psychiatry , 1995, 152(3):473-4.

Kurlan R, Como PG, Deeley C, et al, "A Pilot Controlled Study of Fluoxetine for Obsessive-Compulsive Symptoms in Children With Tourette's Syndrome," Clin Neuropharmacol , 1993, 16(2):167-72.

Lejoyeux M, et al, "Serotonin Syndrome: Incidence, Symptoms, and Treatment," CNS Drugs , 1994, 2:132-43.

Lemberger L, Bergstrom RF, Wolen RL, et al, "Fluoxetine: Clinical Pharmacology and Physiologic Disposition," J Clin Psychiatry , 1985, 46(3 Pt 2):14-9.

McKenzie LJ and Risch SC, "Fibrocystic Breast Disease Following Treatment With Selective Serotonin Reuptake Inhibitors," Am J Psychiatry , 1995, 152(3):471.

Mokhlesi B, Leikin JB, Murray P, et al, "Adult Toxicology in Critical Care: Part II: Specific Poisonings," Chest , 2003, 123(3):897-922.

Murthy R, Newton K, and Qureshi J, "The Association of Fluoxetine With Seizures," J Psychopharmacol , 1994, 8(3):187-8.

Norden MJ, "Buspirone Treatment of Sexual Dysfunction Associated With Selective Serotonin Re-Uptake Inhibitors," Depression , 1994, 2:109-12.

Pollak PT, Sketris IS, MacKenzie SL, et al, "Delirium Probably Induced by Clarithromycin in a Patient Receiving Fluoxetine," Ann Pharmacother , 1995, 29(5):486-8.

Reilly JG, Ayis SA, Ferrier IN, et al, "QTc-Interval Abnormalities and Psychotropic Drug Therapy in Psychiatric Patients," Lancet , 2000, 355(9209):1048-52.

Riddle MA, Hardin MT, King R, et al, "Fluoxetine Treatment of Children and Adolescents With Tourette's and Obsessive-Compulsive Disorders: Preliminary Clinical Experience," J Am Acad Child Adolesc Psychiatry , 1990, 29(1):45-8.

Riddle MA, Scahill L, King RA, et al, "Double-Blind, Crossover Trial of Fluoxetine and Placebo in Children and Adolescents With Obsessive-Compulsive Disorder," J Am Acad Child Adolesc Psychiatry , 1992, 31(6):1062-9.

Roose SP, Glassman AH, Attia E, et al, "Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia," Am J Psychiatry , 1994, 151(12):1735-9.

Schone W and Ludwig M, "A Double-Blind Study of Paroxetine Compared With Fluoxetine in Geriatric Patients With Major Depression," J Clin Psychopharmacol , 1993, 13(6 Suppl 2):34-9.

Spiller HA, Morse S, and Muir C, "Fluoxetine Ingestion: A One Year Retrospective Study," Vet Hum Toxicol , 1990, 32(2):153-5.

Steiner M, Steinberg S, Stewart D, et al, "Fluoxetine in the Treatment of Premenstrual Dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group," N Engl J Med , 1995, 332(23):1529-34.

Sternbach H, "Fluoxetine-Clomipramine Interaction," J Clin Psychiatry , 1995, 56(4):171-2.

Wynn RL, "New Antidepressant Medications," Gen Dent , 1997, 45(1):24-8.


International Brand Names

 Actan® (CL, EC); Adofen® (ES); Afeksin® (DK); Affectine® (IL); Affex® (IE); Aldofen® (ES); Alental® (AR); Alentol® (CL); Alti-Fluoxetine (CA); Alzac® (GT, HN, SV); Andep® (ID); Andepin® (PL); Animex-On® (AR); Anisimol® (CL); Ansilan® (CO); Antiprestin® (ID); Anxetin® (HK, JO, KW, LB, MT, MY, RO); Anzac® (TH); Apo-Flox® (PL); Apo-Fluoxetine® (CA, CZ, HU, RU, SG, ZA); Astrin® (ES); ATD-20® (TH); Auscap® (AU); Azur® (IT); Bioxetin® (PL); Biozac® (IE); Chem mart Fluoxetine® (AU); Clexiclor® (IT); Clinium® (CL); Cloridrato de Fluoxetina® (BR); Cloriflox® (IT); CO Fluoxetine (CA); Courage® (ID); Daforin® (BR); Dagrilan® (GR); DBL Fluoxetine® (AU); Depil® (BD); Depreks® (TR); Deprenon® (CZ, PL); Depress® (BR); Deprex® (CZ, RU); Deprexen® (IT); Deprexetin® (PL); Deprexin® (HU, SG); Deproxin® (TH); Depset® (TR); Diesan® (IT); Digassim® (PT); Dominium® (CL); Eburnate® (AR); Equilibrane® (AR); Erocap® (AU); Eufor® (BR); Faboxetina® (AR); Fefluzin® (HU); Felicium® (AT, GB); Florak® (TR); Flotina® (IT); Floxet® (CZ, HU, RO, RU); Fluctin® (DE); Fluctine® (AT, CH); Flucti-nerton® (DE); Fludac® (IN, ZA); Flumed® (TH); Flumirex® (CZ); Flunat® (RU); Fluneurin® (DE); Flunirin® (YU); Fluocim® (CH, RO); Fluohexal® (AU); Fluoksetyna® (PL); Fluopiram® (AR); Fluox AbZ® (DE); Fluoxac® [tabs] (MX); Fluoxal® (FI); Fluox-basan® (CH); Fluox Basics® (DE); FluoxeLich® (DE); Fluoxemerck® (DE); Fluoxe-Q® (DE); Fluoxeren® (IT); Fluoxetin 1A Farma® (DK); Fluoxetin 1A Pharma® (AT, DE); Fluoxetina Agen® (ES); Fluoxetina Alacan® (ES); Fluoxetina Alpharma® (PT); Fluoxetina Alter® (ES, PT); Fluoxetina Bayvit® (ES); Fluoxetina Belmac® (ES); Fluoxetina Bexal® (ES); Fluoxetina BIG® (IT); Fluoxetina Biochemie® (CO); Fluoxetina® (BR, CL, EC); Fluoxetina Calox® (CR, PA); Fluoxetina Cantabria® (ES); Fluoxetina Ceninter® (ES); Fluoxetina Ciclum® (PT); Fluoxetina Cinfa® (ES); Fluoxetina Combino Pharm® (ES); Fluoxetina Cuve® (ES); Fluoxetina Davur® (ES); Fluoxetina DOC® (IT); Fluoxetina Dorom® (IT); Fluoxetina Edigen® (ES); Fluoxetina EG® (IT); Fluoxetina Esteve® (ES); Fluoxetina Fabra® (AR); Fluoxetina Ferrer Farma® (ES); Fluoxetina Fidia® (IT); Fluoxetina Geminis® (ES); Fluoxetina Generis® (PT); Fluoxetina Genfar® (EC); Fluoxetina GNR® (IT); Fluoxetina Grapa® (ES); Fluoxetina Hexan® (IT); Fluoxetina ICN® (ES); Fluoxetina Irex® (PT); Fluoxetina ITF® (PT); Fluoxetina Kern® (ES); Fluoxetina Lareq® (ES); Fluoxetina Lasa® (ES); Fluoxetin AL® (DE); Fluoxetin Alpharma® (DK); Fluoxetina Mabo® (ES); Fluoxetina Merck® (ES, IT, PT); Fluoxetina MK® (CO); Fluoxetina Normon® (ES); Fluoxetina Pharmagenus® (ES); Fluoxetina Pliva® (IT); Fluoxetina Qualix® (ES); Fluoxetina Ratiopharm® (ES); Fluoxetina-ratiopharm® (IT); Fluoxetin Arcana® (AT); Fluoxetina Rimafar® (ES); Fluoxetina Rubio® (ES); Fluoxetina Sumol® (ES); Fluoxetina Tamarang® (ES); Fluoxetina Teva® (IT); Fluoxetina Vir® (ES); Fluoxetin Azu® (DE); Fluoxetin beta® (DE); Fluoxetin Biochemie® (DK, FI, SE); fluoxetin-biomo® (DE); Fluoxetin-Chinoin® (HU); Fluoxetin-Cophar® (CH); Fluoxetine "1A Farma"® (DK); Fluoxetine-Akri® (RU); Fluoxetine-BC (AU); Fluoxétine Bouchara-Recordati® (FR); Fluoxetine EG® (BE); Fluoxetine® (GB); Fluoxetine Irex® (FR); Fluoxetine Lannacher® (RU); Fluoxetine Nycomed® (RU); Fluoxetine Ranbaxy® (FI); Fluoxetine Stada® (FI); Fluoxetin Genericon® (AT); Fluoxetin Generics® (FI); Fluoxetin Helvepharm® (CH); Fluoxetin Heumann® (DE); Fluoxetin KSK® (DE); Fluoxetin Lindo® (DE); Fluoxetin-Mepha® (CH); Fluoxetin-neuraxpharm® (DE); Fluoxetin NM® (DK, NO); Fluoxetin® (NO, PL, RO); Fluoxetin-ratiopharm® (DE); Fluoxetin ratiopharm® (SE); Fluoxetin-RPh® (DE); Fluoxetin Sandoz® (DE, DK); Fluoxetin Selena® (SE); Fluoxetin Stada® (DE); Fluoxetin TAD® (DE); Fluoxetin-TEVA® (DE); fluoxetin von ct® (DE); Fluoxgamma® (DE); Fluoxibene® (AT); Fluoxifar® (CH); Fluoxil® (DO); Fluoxin® (CZ, IT, RO); Fluoxine® (TH); Fluox® (NZ); Fluoxone Divule® (BE); Fluox-Puren® (DE); Fluozac® (AR); Flusac® (TH); Flusetin® (YU); Flusol® (CH); Flutin® (CO, DK); Flutine® (IL, TH); Fluval® (CZ, HR, RU, SI); Fluxal® (DO); Flux® (AT); Fluxene® (BR); Fluxet® (DE); Fluxetil® (SG, TH); Fluxetin Atlantic® (TH); Fluxetin® (SG); Fluxilan® (YU); Fluxil® (AT); Fluxin® (PL); FluxoMed® (AT); Fluxonil® (CZ, RO, RU); Fluzac-20® (TH); Folizol® (DK); Fondur® (DK); Fontex® (BE, DK, FI, NO, SE); Fonzac® (DK); Foxetin® (AR); Framex® (CZ, RO, RU); Fulsac® (TR); FXT (CA); Gen-Fluoxetine (CA); GenRX Fluoxetine® (AU); Gerozac® (IE); Grinflux® (IT); Hapilux® (TH); Healthsense Fluoxetine® (AU); Huma-Fluoxetin® (HU); Ibixetin® (IT); Kalxetin® (ID); Lecimar® (ES); Lilly-Fluoxetine® (ZA); Lodep® (ID); Loksetin® (TR); Lorien Capsules® (ZA); Lovan® (AU, NZ); Loxetine-20® (TH); Luminal® (EC); Magrilan® (CZ, RO, SG, TH, VN); Merck-Fluoxetine® (BE); Mitilase® (AR); Modipran® (BD); Moltoben® (CO, DO, GT, HN, PA, SV); Motivone® (DE); Mutan® (AT); Nervosal® (AR); Neupax® (AR, CR, DO, GT, HN, PA, SV); Nodep® (BD); Nodepe® (ES, PT); Nopres® (ID); Nor-Presin® (SV); Nortec® (BR); Norzac® (IE); Novo-Fluoxetine (CA); Nu-Fluoxetine (CA); Nuzak® (ZA); Oxactin® (GB); Oxetine® (TH); Oxsac® (TH); Platin® (IN); Plazeron® (CY); Plinzene® (NZ); PMS-Fluoxetine (CA); Portal® (CZ, HR, HU, RO, RU, SI); Positivum® (AT); Pragmaten® (CL, CO); Prizma® (IL); Prodep® (BD, RU, TH); Proflusak® (RU); Prohexal® (ZA); Prolert® (BD); Prozac® (AR, AU, BD, BE, BR, CA, CL, CO, CR, CZ, DO, ES, FR, GB, GT, HK, HN, HR, HU, ID, IE, IL, IT, LU, MX, NL, NZ, PA, PL, PT, RO, RU, SG, SI, SV, TH, TR, ZA); Prozac Orifarm® (DK); Prozamel® (IE); Prozatan® (IE); Prozit® (IE); Psipax® (PT); Psiquial® (BR); Ranflocs® (ZA); Refloksetin® (YU); Reneuron® (ES); Rhoxal-fluoxetine (CA); Rowexetina® (CR, DO, EC, HN, PA, SV); Rozax® (JO, RO); Salipax® (EC, PT, SI); Sandoz-Fluoxetine® (ZA); Sanzur® (ZA); Saurat® (AR); SBPA Fluoxetine® (AU); Seromex® (FI); Seronil® (FI, PL); Seroscand® (SE); Siquial® [caps] (MX); Sostac® (CL); Terry White Chemists Fluoxetine® (AU); Tremafarm® (CL); Tuneluz® (PT); Unprozy® (TH); Verotina® (BR); Xeredien® (IT); Xetiran® (PL); Zac® (ID); Zactin® (AU, SG); Zedprex® (TR); Zepax® (CO)


A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-2007 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
adam.com